To: technetium who wrote (345 ) 12/15/2007 10:16:52 AM From: Casaubon Respond to of 397 Nice charity. My check will go out this weekend for $200.00. Now for some strategy discussion. I backend loaded my portfolio with companies that would have significant clinical trial news towards the end of the year. The hope was to get some pops that wouldn't fade to nothing (a risk if the pop happens too early in the year). Also, the companies represented takeover candidates for big pharma, who are flush with cash from repatriation of dollars earned outside the US. Takeovers are great in the competition because, they lock in gains. In real life, this might not maximize your profit potential but, in the game, it forces your hand to the plus side. There was some risk to the strategy. Delays in critical clinical filings throws a monkey wrench into the strategy. Also, for some reason, there was far less M&A activity than I had anticipated this year. Perhaps that was a result of the sub-prime freeze up, but that shouldn't really effect pharma with cash and weak pipline. Now for a synopsis: I had 2 outright blowups and 5 losers. One do nothing and, 2 winners. With the diversification, I only finished 6.5% to the bad. Considering the magnitude of some of the losses this was not bad. I spent 51 weeks off the leader board somewhere in the biotech backwaters. My conclusion: Pick companies working on sound science programs (for the most part, money will fall out of the equation over time). This requires knowledge of proposed disease mechanisms (non-scientific people should probably stick to mutual funds for biotech exposure). Evaluate the size of the market potential. Only a small percentage (I think about 20%) of compounds entering the clinic ever graduate to drug status. Only about half of those are considered commercial success stories. This is a tough game.